KMT2A and leukemia: They found that this inhibitor had a strong effect on the survival of MLL-rearranged leukaemia cells derived from patients, and this was partly due to the inhibition of transcription of BCL-2, the oncogene C-MYC and CDK6, the latter of which is required for the exit of haematopoietic stem cells from quiescence [102].